Combination of antiretroviral drugs and radioimmunotherapy specifically kills infected cells from HIV-Infected individuals

Dina Tsukrov, Alicia McFarren, Alfred Morgenstern, Frank Bruchertseifer, Eugene Dolce, Miroslaw K. Gorny, Susan Zolla-Pazner, Joan W. Berman, Ellie Schoenbaum, Barry S. Zingman, Arturo Casadevall, Ekaterina Dadachova

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Eliminating virally infected cells is an essential component of any HIV eradication strategy. Radioimmunotherapy (RIT), a clinically established method for killing cells using radiolabeled antibodies, was recently applied to target HIV-1 gp41 antigen expressed on the surface of infected cells. Since gp41 expression by infected cells is likely downregulated in patients on antiretroviral therapy (ART), we evaluated the ability of RIT to kill ART-treated infected cells using both in vitro models and lymphocytes isolated from HIV-infected subjects. Human peripheral blood mononuclear cells (PBMCs) were infected with HIV and cultured in the presence of two clinically relevant ART combinations. Scatchard analysis of the 2556 human monoclonal antibody to HIV gp41 binding to the infected and ART-treated cells demonstrated sufficient residual expression of gp41 on the cell surface to warrant subsequent RIT. This is the first time the quantification of gp41 post-ART is being reported. Cells were then treated with Bismuth-213-labeled 2556 antibody. Cell survival was quantified by Trypan blue and residual viremia by p24 ELISA. Cell surface gp41 expression was assessed by Scatchard analysis. The experiments were repeated using PBMCs isolated from blood specimens obtained from 15 HIV-infected individuals: 10 on ART and 5 ART-naïve. We found that 213 Bi-2556 killed ART-treated infected PBMCs and reduced viral production to undetectable levels. ART and RIT co-treatment was more effective at reducing viral load in vitro than either therapy alone, indicating that gp41 expression under ART was sufficient to allow 213 Bi-2556 to deliver cytocidal doses of radiation to infected cells. This study provides proof of concept that 213 Bi-2556 may represent an innovative and effective targeting method for killing HIV-infected cells treated with ART and supports continued development of 213 Bi-2556 for co-administration with ART toward an HIV eradication strategy.

Original languageEnglish (US)
Article number41
JournalFrontiers in Medicine
Volume3
Issue numberSEP
DOIs
StatePublished - Jan 1 2016

Fingerprint

Radioimmunotherapy
Drug Combinations
HIV
Therapeutics
Blood Cells
HIV Envelope Protein gp41
Bismuth
Trypan Blue
Antibodies
Viremia
Cell- and Tissue-Based Therapy
Viral Load

Keywords

  • Antiretroviral therapy
  • Bismuth-213
  • Gp41
  • HIV
  • Patients
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tsukrov, D., McFarren, A., Morgenstern, A., Bruchertseifer, F., Dolce, E., Gorny, M. K., ... Dadachova, E. (2016). Combination of antiretroviral drugs and radioimmunotherapy specifically kills infected cells from HIV-Infected individuals. Frontiers in Medicine, 3(SEP), [41]. https://doi.org/10.3389/fmed.2016.00041

Combination of antiretroviral drugs and radioimmunotherapy specifically kills infected cells from HIV-Infected individuals. / Tsukrov, Dina; McFarren, Alicia; Morgenstern, Alfred; Bruchertseifer, Frank; Dolce, Eugene; Gorny, Miroslaw K.; Zolla-Pazner, Susan; Berman, Joan W.; Schoenbaum, Ellie; Zingman, Barry S.; Casadevall, Arturo; Dadachova, Ekaterina.

In: Frontiers in Medicine, Vol. 3, No. SEP, 41, 01.01.2016.

Research output: Contribution to journalArticle

Tsukrov, D, McFarren, A, Morgenstern, A, Bruchertseifer, F, Dolce, E, Gorny, MK, Zolla-Pazner, S, Berman, JW, Schoenbaum, E, Zingman, BS, Casadevall, A & Dadachova, E 2016, 'Combination of antiretroviral drugs and radioimmunotherapy specifically kills infected cells from HIV-Infected individuals', Frontiers in Medicine, vol. 3, no. SEP, 41. https://doi.org/10.3389/fmed.2016.00041
Tsukrov, Dina ; McFarren, Alicia ; Morgenstern, Alfred ; Bruchertseifer, Frank ; Dolce, Eugene ; Gorny, Miroslaw K. ; Zolla-Pazner, Susan ; Berman, Joan W. ; Schoenbaum, Ellie ; Zingman, Barry S. ; Casadevall, Arturo ; Dadachova, Ekaterina. / Combination of antiretroviral drugs and radioimmunotherapy specifically kills infected cells from HIV-Infected individuals. In: Frontiers in Medicine. 2016 ; Vol. 3, No. SEP.
@article{b80f5c6c48d948218de7f30ece56e91f,
title = "Combination of antiretroviral drugs and radioimmunotherapy specifically kills infected cells from HIV-Infected individuals",
abstract = "Eliminating virally infected cells is an essential component of any HIV eradication strategy. Radioimmunotherapy (RIT), a clinically established method for killing cells using radiolabeled antibodies, was recently applied to target HIV-1 gp41 antigen expressed on the surface of infected cells. Since gp41 expression by infected cells is likely downregulated in patients on antiretroviral therapy (ART), we evaluated the ability of RIT to kill ART-treated infected cells using both in vitro models and lymphocytes isolated from HIV-infected subjects. Human peripheral blood mononuclear cells (PBMCs) were infected with HIV and cultured in the presence of two clinically relevant ART combinations. Scatchard analysis of the 2556 human monoclonal antibody to HIV gp41 binding to the infected and ART-treated cells demonstrated sufficient residual expression of gp41 on the cell surface to warrant subsequent RIT. This is the first time the quantification of gp41 post-ART is being reported. Cells were then treated with Bismuth-213-labeled 2556 antibody. Cell survival was quantified by Trypan blue and residual viremia by p24 ELISA. Cell surface gp41 expression was assessed by Scatchard analysis. The experiments were repeated using PBMCs isolated from blood specimens obtained from 15 HIV-infected individuals: 10 on ART and 5 ART-na{\"i}ve. We found that 213 Bi-2556 killed ART-treated infected PBMCs and reduced viral production to undetectable levels. ART and RIT co-treatment was more effective at reducing viral load in vitro than either therapy alone, indicating that gp41 expression under ART was sufficient to allow 213 Bi-2556 to deliver cytocidal doses of radiation to infected cells. This study provides proof of concept that 213 Bi-2556 may represent an innovative and effective targeting method for killing HIV-infected cells treated with ART and supports continued development of 213 Bi-2556 for co-administration with ART toward an HIV eradication strategy.",
keywords = "Antiretroviral therapy, Bismuth-213, Gp41, HIV, Patients, Radioimmunotherapy",
author = "Dina Tsukrov and Alicia McFarren and Alfred Morgenstern and Frank Bruchertseifer and Eugene Dolce and Gorny, {Miroslaw K.} and Susan Zolla-Pazner and Berman, {Joan W.} and Ellie Schoenbaum and Zingman, {Barry S.} and Arturo Casadevall and Ekaterina Dadachova",
year = "2016",
month = "1",
day = "1",
doi = "10.3389/fmed.2016.00041",
language = "English (US)",
volume = "3",
journal = "Frontiers in Medicine",
issn = "2296-858X",
publisher = "Frontiers Media S. A.",
number = "SEP",

}

TY - JOUR

T1 - Combination of antiretroviral drugs and radioimmunotherapy specifically kills infected cells from HIV-Infected individuals

AU - Tsukrov, Dina

AU - McFarren, Alicia

AU - Morgenstern, Alfred

AU - Bruchertseifer, Frank

AU - Dolce, Eugene

AU - Gorny, Miroslaw K.

AU - Zolla-Pazner, Susan

AU - Berman, Joan W.

AU - Schoenbaum, Ellie

AU - Zingman, Barry S.

AU - Casadevall, Arturo

AU - Dadachova, Ekaterina

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Eliminating virally infected cells is an essential component of any HIV eradication strategy. Radioimmunotherapy (RIT), a clinically established method for killing cells using radiolabeled antibodies, was recently applied to target HIV-1 gp41 antigen expressed on the surface of infected cells. Since gp41 expression by infected cells is likely downregulated in patients on antiretroviral therapy (ART), we evaluated the ability of RIT to kill ART-treated infected cells using both in vitro models and lymphocytes isolated from HIV-infected subjects. Human peripheral blood mononuclear cells (PBMCs) were infected with HIV and cultured in the presence of two clinically relevant ART combinations. Scatchard analysis of the 2556 human monoclonal antibody to HIV gp41 binding to the infected and ART-treated cells demonstrated sufficient residual expression of gp41 on the cell surface to warrant subsequent RIT. This is the first time the quantification of gp41 post-ART is being reported. Cells were then treated with Bismuth-213-labeled 2556 antibody. Cell survival was quantified by Trypan blue and residual viremia by p24 ELISA. Cell surface gp41 expression was assessed by Scatchard analysis. The experiments were repeated using PBMCs isolated from blood specimens obtained from 15 HIV-infected individuals: 10 on ART and 5 ART-naïve. We found that 213 Bi-2556 killed ART-treated infected PBMCs and reduced viral production to undetectable levels. ART and RIT co-treatment was more effective at reducing viral load in vitro than either therapy alone, indicating that gp41 expression under ART was sufficient to allow 213 Bi-2556 to deliver cytocidal doses of radiation to infected cells. This study provides proof of concept that 213 Bi-2556 may represent an innovative and effective targeting method for killing HIV-infected cells treated with ART and supports continued development of 213 Bi-2556 for co-administration with ART toward an HIV eradication strategy.

AB - Eliminating virally infected cells is an essential component of any HIV eradication strategy. Radioimmunotherapy (RIT), a clinically established method for killing cells using radiolabeled antibodies, was recently applied to target HIV-1 gp41 antigen expressed on the surface of infected cells. Since gp41 expression by infected cells is likely downregulated in patients on antiretroviral therapy (ART), we evaluated the ability of RIT to kill ART-treated infected cells using both in vitro models and lymphocytes isolated from HIV-infected subjects. Human peripheral blood mononuclear cells (PBMCs) were infected with HIV and cultured in the presence of two clinically relevant ART combinations. Scatchard analysis of the 2556 human monoclonal antibody to HIV gp41 binding to the infected and ART-treated cells demonstrated sufficient residual expression of gp41 on the cell surface to warrant subsequent RIT. This is the first time the quantification of gp41 post-ART is being reported. Cells were then treated with Bismuth-213-labeled 2556 antibody. Cell survival was quantified by Trypan blue and residual viremia by p24 ELISA. Cell surface gp41 expression was assessed by Scatchard analysis. The experiments were repeated using PBMCs isolated from blood specimens obtained from 15 HIV-infected individuals: 10 on ART and 5 ART-naïve. We found that 213 Bi-2556 killed ART-treated infected PBMCs and reduced viral production to undetectable levels. ART and RIT co-treatment was more effective at reducing viral load in vitro than either therapy alone, indicating that gp41 expression under ART was sufficient to allow 213 Bi-2556 to deliver cytocidal doses of radiation to infected cells. This study provides proof of concept that 213 Bi-2556 may represent an innovative and effective targeting method for killing HIV-infected cells treated with ART and supports continued development of 213 Bi-2556 for co-administration with ART toward an HIV eradication strategy.

KW - Antiretroviral therapy

KW - Bismuth-213

KW - Gp41

KW - HIV

KW - Patients

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85055628986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055628986&partnerID=8YFLogxK

U2 - 10.3389/fmed.2016.00041

DO - 10.3389/fmed.2016.00041

M3 - Article

AN - SCOPUS:85055628986

VL - 3

JO - Frontiers in Medicine

JF - Frontiers in Medicine

SN - 2296-858X

IS - SEP

M1 - 41

ER -